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Abstract 
 
The gene Jarid1c plays an important role in brain function. Human mutations in Jarid1c 
cause mental retardation and autistic behaviors. This study looks into the importance of Jarid1c 
in specific brain regions speculated to be involved in autism. Knockdown of Jarid1c in BL/6 
mice was performed using stereotaxic injection of Jarid1c-siRNA into the hippocampus, 
amygdala, and cortex. Controls were given a non-targeting siRNA. Behavior testing was 
performed two days post-surgery and microarray analysis was performed to confirm knockdown. 
It was found that Jarid1c knockdown in the hippocampus significantly reduces the mouse’s 
ability to perform well on an object recognition test. It was also found that Jarid1c knockdown in 
the prefrontal cortex significantly increases the mouse’s anxiety.  
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Background 
Jarid1c and its link to mental retardation  
 
Mental retardation is a non-progressive cognitive impairment that affects 2-3% of the 
population (Chelly, 1999).  Yet, even given the high frequency this disease appears in the 
population, research has largely neglected to find the causes of this disease. It has been 
discovered, however, that many genes connected to mental retardation are found on the X 
chromosome. This led to the discovery of a number of types of retardation now generally termed 
X-linked mental retardation (XLMR) (Chelly, 1999). 
X-linked mental retardation is a heterogeneous disease affecting 2 out of every 1000 
males. Many genes have been discovered to have a link to XLMR; one of the more recently 
discovered genes is Jarid1c. While there have been several other genes identified as possible 
causes of XLMR, Jarid1c has shown to be one of the most frequently mutated causal genes in 
this disease (Iwase et al., 2007). In humans, mutations in the Jarid1c gene cause neurological 
disorders including mental retardation, epilepsy, aggression, and autism.   
In a study done in Australia in 2004, families with nonsyndromic X-linked mental 
retardation were studied and Jarid1c was discovered as a gene of interest in human brain 
function. Seven mutations were found in the gene among the patients studied and mutations in 
Jarid1c were found in 2 of 31 families investigated (Jensen et al., 2005). Through further 
investigation it was discovered that Jarid1c encodes a number of proteins involved in 
transcriptional regulation and chromatin remodeling. In the study, Northern blot analysis was 
performed for 6 affected males as well as 5 male controls. Two out of six of the affected males 
tested showed a significant reduction of Jarid1c transcripts, which would likely result in a non-
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functional Jarid1c protein. Given the results of this study, it is now believed that the Jarid1c 
mutations detected significantly affect the function of the protein and are responsible for the 
cognitive deficits associated with the patients in this study (Jensen et al., 2005). 
Jensen et al. (2005) also discovered that Jarid1c in humans is evolutionarily conserved 
with homologs in the mouse. This makes the mouse model an excellent tool for further research, 
since the Jarid1c gene plays the same role in mice as it does in the human brain. One interesting 
difference, however, is that in mice, Jarid1c is expressed at significantly higher levels in the adult 
female than in the male. Given this discrepancy between female and male mice, it would make a 
knockdown of Jarid1c in a male mouse brain hold more significance than in a female mouse 
brain. A male mouse would be a better model because there would be less compensation of the 
lost Jarid1c function elsewhere in the brain. For example, 25% knockdown in a male mouse 
would be more significant than 25% knockdown in a female since the male started off with a 
lower Jarid1c function level (Jensen et al., 2005).   
Jarid1c has proven to be important in other species as well. In a 2007 study by Iwase et 
al., the influence of Jarid1c on neuronal survival and dendrite development was studied using 
zebrafish embryos and mammalian cells. Results indicated that Jarid1c was present throughout 
the fish’s embryogenesis, with ubiquitous expression in early stages and then expression isolated 
to the head in later stages. These results suggest that Jarid1c plays a valuable role in neuronal 
development and survival in the zebrafish (Iwase et al., 2007).  In this study Jarid1c function was 
also observed in mammalian neurons. Granule neurons from rodent cerebellar cortex were used 
for this study. Gene knockdown was performed using plasmid-based RNAi in cells cultured from 
a postnatal day six rat. It was found that knockdown led to a significant reduction in dendritic 
length of neurons. This suggests that Jarid1c plays an important role in dendritic development in 
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the rodent brain (Iwase et al., 2007). Given these findings, Jarid1c may play a significant role in 
neuronal development in the human brain as well, since the gene functions similarly in both 
species.  
In the same study (Iwase et al., 2007), Jarid1c was discovered to be responsible for 
catalyzing demethylation of certain histones. In vitro, over expression of Jarid1c was tested and 
it was found to result in specific reduction of histones, in support of previous findings. The 
missense mutations in Jarid1c that were previously found to be related to XLMR were shown to 
specifically affect the genes’ demethylation ability as well as its ability to bind the histones. This 
suggests that Jarid1c’s demethylation ability is pertinent to understanding the causes of XLMR. 
To further test this idea, Jarid1c was inhibited by in situ hybridization in zebrafish. Significant 
neuronal defects were found as well as increased neuronal cell death in zebrafish with inhibited 
Jarid1c (Iwase et al., 2007).   
 
siRNA 
 
Small interfering RNAs (siRNAs) are used to transiently silence a target gene. They 
mimic intermediates in the RNAi pathway, suppress the targeted genes’ expression, and do not 
influence expression of non-targeted genes (McCaffrey et al., 2002). Specifically, siRNA cleaves 
cytoplasmic mRNAs containing sequences that are homologous to that specific siRNAs double 
stranded RNA (dsRNA) trigger as shown in Figure 1 (Thakker et al., 2004).  
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Figure 1: RNA-induced silencing complex 
 
McCaffrey et al. (2002) studied the ability of siRNA to work in vivo. They tested adult 
rats by injecting firefly luciferase into their liver along with luciferase targeting siRNA and an 
unrelated siRNA as a control. The ability of the luciferase siRNA to down regulate gene 
expression was then monitored using the luciferase reporter (Figure 2). Images were taken 72 
hours after injection and results showed significant decrease in luciferase in the mice injected 
with the luciferase siRNA. The controls showed no decrease in luciferase confirming that the 
siRNA specific to luciferase was responsible for the reduction (McCaffrey et al., 2002). 
 
Figure 2: RNA interference in adult mice at 72 hours post-injection (McCaffrey et al., 2002) 
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Once siRNA’s ability to knockdown specific genes in vivo was confirmed, other studies 
confirmed its use in the mammalian brain. In a 2004 study, gene specific siRNA was injected 
into different areas of the mouse brain and tested. The tissue was then analyzed to see if the 
target mRNA knockdown was successful. It was found that siRNA was successful in producing a 
specific and time-dependent reduction of the target gene’s expression in vivo (Thakker et al., 
2004). This study confirmed that siRNA could successfully be used in the mammalian brain for 
specific gene silencing.  
 
Stereotaxic injection 
 
Stereotaxic injection is an invaluable tool that is quickly becoming more popular for gene 
manipulation in the neuroscience field. There are many benefits of stereotaxic injection over 
traditional gene manipulation methods. The use of stereotaxic injection allows for site specific 
gene knockdown in combination with a targeted siRNA.  It also allows for targeting of any brain 
region, which was much more difficult before the use of stereotaxic injection. Furthermore, 
knockdown spreading to other non-targeted regions of the brain is minimized when using proper 
stereotaxic procedure. The main benefit of stereotaxic injection is the exceptional spatiotemporal 
control. Exact coordinates for the target brain region can be established using a mouse atlas such 
as the atlas created by Paxinos & Franklin (2001).  This procedure insures that the correct area is 
being targeted and avoids variables such as gene alterations which occur when using more 
traditional mouse genetics (Cetin et al., 2007).  
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Brain regions 
 
Different brain regions have been targeted for siRNA gene knockdown in previous 
studies. In one study (Thakker et al., 2004), an enhanced green fluorescent protein gene (EGFP) 
was targeted and EGFP-siRNA was injected into the dorsal third ventricle to allow for bilateral 
and widespread distribution of the target siRNA in the mouse brain. siRNA was infused for one 
week and then 17 brain regions were tested for knockdown success. As shown in Figure 3, 
down-regulation of EGFP mRNA was successful in 11 of 17 brain regions tested. The highest 
knockdown was recorded in those areas closest to the injection point. 
 
Figure 3: siRNA-induced specific, temporal, and widespread knockdown of EGFP mRNA 
in the brain (Thakker et al., 2004) 
 
In another test, knockdown of the gene GluR2 and its protein, Cox-1, was performed in 
the rat brain using electroporation to deliver gene specific siRNA to certain brain regions 
(Akaneya et al., 2005). The visual cortex was targeted in one test and the hippocampus in 
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another. In both cases there was successful gene and protein knockdown and knockdown was 
specific to the targeted brain region. This study was very important in that it showed that 
knockdown spreading could be avoided using proper stereotaxic injection techniques.  
The amygdala, prefrontal cortex and hippocampus are all associated with behaviors 
common to children suffering from autism or other similar XLMR diseases. The amygdala is 
part of what is known as the “social brain” and therefore is often the target of autistic research. In 
a study (Baron-Cohen et al., 2000) that used magnetic resonance imaging (MRI) it was found 
that the amygdala is not activated in children with autism when making inferences from the eyes. 
However, in people without autism, MRI showed significant amygdala activity during the same 
tests. This study shows promise for furthering autism research and focusing on the importance of 
the amygdala. 
The prefrontal cortex has also been found to play a role in autistic behavior (Ohnishi et 
al., 2000). The prefrontal cortex is important for communication as well as social interaction. In 
a study involving neuroimaging of autistic patients, it was found that patients suffering from 
autism had altered perfusion in the medial prefrontal cortex when compared to control patients. 
These alterations suggest possible abnormalities in brain function that may cause the behaviors 
associated with autistic patients. The alterations in perfusion were especially apparent in those 
patients suffering from behavior such as deficits in theory of mind, abnormal sensory responses, 
and an obsession for sameness. 
The hippocampus is important for long term memory as well as spatial navigation. It is 
also densely packed with neurons and therefore proves to be a good model for neurophysiology 
studies. In a study that performed neuronal analysis on two children suffering from autism, it was 
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found that their hippocampal neurons were smaller in area and dendritic branching than age-
matched controls (Raymond et al., 1996). This supports the idea that children suffering from 
autism have slowed maturation of neurons and that the hippocampus may play an important role 
in autistic behaviors. 
 
RNA extraction 
 
In order to analyze if the siRNA was successful at silencing the targeted gene in the area 
of injection, RNA extraction post-mortem is necessary. RNA extraction is commonly 
accomplished using reverse transcriptase kits provided by the company Qiagen. For the mRNA 
extraction, the Qiagen’s RNAeasy kit (Qiagen, Valencia, CA) has proven to be effective with 
many different tissues including brain matter, saliva, and buccal cells. It contains relatively easy 
steps and materials that allow for sufficient mRNA extraction before PCR (Spivack et al., 2004). 
Once RNA has been successfully extracted from the tissue sample, real-time PCR can be 
performed with known primers (Ball et al., 2002).  
 
Behavior testing 
 
 Object recognition tests have been performed on mice to assess changes in memory 
function. A normal mouse, when faced with a familiar and a novel object, should spend more 
time with the novel object (Figure 4), since mice are naturally curious. The mouse’s attention to 
the novel object will usually consist of sniffing and approaching the object from different angles. 
Studies involving a mouse with lowered memory capabilities have shown that the mouse with 
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lowered memory function, when faced with a familiar and novel object, will not remember the 
familiar object and will therefore treat both objects as novel (Reibaud et al., 1999). Tests have 
also been done involving the enhancement of a mouse’s memory capabilities. Object recognition 
testing with memory enhanced mice showed greater ability of those mice to remember the 
familiar object for longer periods of time, and therefore show increased attention to the novel 
object over that longer time span (Reibaud et al., 1999).  
 
Figure 4: Object Recognition test 
 To test the anxiety of a mouse, an open field test can be administered. In an enclosed 
area, a normal mouse will stay close to the walls for a while, then become curious and venture 
out into the middle of the open field. However, an anxious mouse will remain almost exclusively 
at the walls of the enclosure (Figure 5). In one study, high-anxiety mice were created by using a 
targeting vector to limit corticotrophin-releasing hormones. Their anxiety was confirmed using 
an open field test (Bale et al., 2000). 
15 
 
 
Figure 5: Open field test for Anxiety 
Previous research in this lab  
 
Previous research in this lab has been conducted involving Jarid1c and its effect on 
behavior when knocked down in the hippocampus. During a study performed by Marc Siegel, 
Liz Byrnes, Ph.D, and Jun Xu, Ph.D, Jarid1c was knocked down using gene specific siRNA. 
Four female C57 BL/6 mice were injected bilaterally with Jarid1c-siRNA using stereotaxic 
injection into their hippocampus. Four additional mice were injected with a non-targeting control 
siRNA. The mice’s behavior was then tested two days post-surgery to allow for the siRNA to 
take full effect, since two to four days post-surgery is optimal for testing. Behavior tests were 
performed for social preference, aggression, and object recognition. Social preference tests the 
mouse’s time spent investigating a novel mouse, aggression tests the mouse’s aggression towards 
the novel mouse and object recognition tests memory as previously described. 
Since this study used female mice, it was important to test their estrogen levels. Estrogen 
levels have been shown to affect behavior, so estrogen levels must be assessed when conducting 
behavior testing on female mice (Fernandez et al., 2008). Therefore, estrogen levels were 
recorded using vaginal smearing after the behavior tests for both the test mice and the control 
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mice. The mice were then categorized into one of two groups, high or low estrogen, depending 
upon their estrogen levels.   
The success of the Jarid1c knockdown was quantified using the RT-PCR method on a 
real-time PCR machine (ABI, Foster City, CA).  It was found that the Jarid1c-siRNA samples 
had a 60% reduction relative to the control samples. This quantitative analysis confirmed the 
effectiveness of the treatment.   
During analysis of the behavior testing, it was found that for both high and low estrogen 
mice, the Jarid1c-siRNA mice spent less time with the stimulus mouse than the controls during 
the social preference test (p < .01). During the object recognition tests it was found that Jarid1c-
siRNA mice spent less time with the novel object than the control mice (p=0.09). However, it 
was also noticed that the level of estrogen affected the performance of the control mice in the 
object recognition test. Those with higher estrogen levels performed better than those with lower 
estrogen levels. This was not seen in the Jarid1c-siRNA treated mice or in any other behavior 
test. It was also found that there was no change in aggression between Jarid1c- and control-
siRNA treated mice. 
In conclusion, this previous study found that in female BL/6 mice, knockdown of Jarid1c 
in the hippocampus caused a lowered desire to socialize. This was displayed by the results in the 
social preference test. Knockdown of Jarid1c in the hippocampus also affected the mouse’s 
memory as shown by the object recognition test. However, the object recognition test also found 
that estrogen levels affect behavior during the testing process for the control mice but not the 
Jarid1c-siRNA treated mice. Lastly, it proved that the use of stereotaxic injection to perform 
gene specific siRNA knockdown in the hippocampus of these mice was successful. To further 
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the investigation into Jarid1c and its ties to XLMR symptoms, this study looks into the 
knockdown affects of Jarid1c in three areas of the mouse brain, the hippocampus, prefrontal 
cortex and amygdala, measured using behavior testing. To date, little is known about the role of 
Jarid1c in different areas of the brain. The three brain regions chosen for investigation in this 
study were selected based on their previously discovered links to autistic and other XLMR 
symptoms in humans. This study hopes to answer questions about the importance of Jarid1c and 
whether XLMR symptoms may be caused by a deficiency of Jarid1c in these specific brain 
regions. 
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Materials and Methods 
Animals 
 
 Male BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME) at 9 weeks of 
age. Each mouse was injected with an AVID chip (Norco, CA) a week after arrival at Tufts 
University to allow for easy identification using the AVID chip reader. Mice were kept on a 
12/12 hour light/dark cycle with water and food available at all times. Mice also received daily 
attention from the research staff at Tufts University. All protocols involving mice were approved 
by the Tufts University Institutional Animal Care and Use Committee.  
 
RNA interference 
 
 Jarid1c-siRNA was obtained from Qiagen (Valencia, CA). Jarid1c-siRNA contains four 
different siRNA sequences that each targets a different site on the Jarid1c mRNA. This broad 
targeting ensures a marked gene knockdown. Target sequences are: 
Jarid1c-3: CAGCTTCGTCGTACCAACTCA 
Jarid1c-6: ACGGCGGATCTTGGACCTCTA 
Jarid1c-1: CGCATTGTTTATCCCTATGAA 
Jarid1c-2: AAGATTGTTGGTGTGTAATTA 
Upon arrival at Tufts University, the siRNA was resuspended in water (7.5 g /1 l) and mixed. 
On the day of surgery 3l of siRNA suspension was mixed with 3l of DOTAP, a transfection 
reagent (Roche, Indianapolis, IN). The same process was done with the control-siRNA which is 
non-targeting.  
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Stereotaxic siRNA delivery. (Detailed protocol is available in Appendix A). 
 
 Four mice were given siRNA injections each surgery day. Two brain regions were chosen 
on each surgery day and for each brain region one mouse received the Jarid1c-siRNA and the 
second received the control-siRNA. For example, on day 1 of surgery one mouse received a 
Jarid1c-siRNA injection in the prefrontal cortex, and one received a control-siRNA injection in 
the prefrontal cortex. Then another two mice received injections following the same procedure in 
the amygdala. The injections were given bilaterally with a concentration of 3.75 g of siRNA in 
1 l. Over 7 surgery days, a total of 26 mice were given injections in the prefrontal cortex, 
hippocampus and amygdala (see Appendix B). Coordinates for each region are shown in Table 1.  
 
In mm relative to Bregma (Paxinos and Franklin, 2001) AP ML VD 
Prefrontal cortex +2.8 +/- 1.6 -1.3 
Hippocampus -2.0 +/-2.0 -1.6 
Amygdala -1.5 +/-2.6 -5.7 
Table 1: Coordinates for targeted brain regions 
 
Isoflourine was used for general anesthesia purposes as well as bupivicaine as a local anesthetic. 
Ketoprofen was given as a pain reducer. Sterile technique was used throughout the surgery and 
post-surgery monitoring was performed until full recovery.  
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Behavior testing (written by contributing author, Alex Newbury, from the College of 
the Holy Cross) 
 
Two days after the siRNA injection, each mouse was tested in three different behavioral 
paradigms: anxiety and activity monitoring, and object recognition. Each test was conducted in 
the same behavioral testing room under relatively constant conditions (i.e. ~70
o
F, 40% 
humidity). Every mouse was first habituated to the room for thirty minutes by being placed in 
our activity monitor. This apparatus quantifies the amount of locomotion for each mouse in thirty 
minutes. Once compiled, this data allows us to ensure that any lack of social or novel object 
interaction is in fact due to a disinterest in our stimulus and not due to any physical motor 
failures.  
 In addition, using the activity software Motor Monitor, we can gauge the amount of 
anxiety in each mouse by looking at the ratio of time spent in the two zones of the testing cage. 
Zone one is located around the perimeter, while zone two is located in the center. Any time spent 
in zone two is considered anxiety provoking, while time spent in zone one is considered to 
provide an anxiolytic effect. Subtracting the time spent in zone two from zone one allows us to 
see how often each mouse engaged in the anxiety provoking behavior, which corresponds to a 
greater amount of time in the center of the cage vs. the perimeter.  
 Once these tests were conducted, object recognition testing was performed. This 
behavioral paradigm must be conducted in two phases, as it tests the cognition and recall ability 
of each test mouse. Phase one consists of introducing each mouse to two identical objects for 
five minutes in a 2x2’ enclosure. In this study, two orange or blue toy cylinders were used at this 
stage. After a consistent latency of two hours and 45 minutes (165 minutes), each mouse was 
reintroduced to the same testing enclosure with one of the same objects from phase one and 
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another completely novel object. In this study, we used orange and blue pyramids. We scored the 
behavior by timing how long it took for the subject to spend thirty seconds with the novel object. 
We did this by running two stopwatches, one for the overall time and one for every time the 
subject was interacting with the novel object. Once thirty seconds was reached, the overall timer 
was stopped, the time was recorded and we returned the subject to its home cage. After each 
trial, both the testing apparatus and the toys were washed with 70% ethanol and then with water 
to remove the EtOH.  
 
Microarray analysis 
 
 Two days post surgery, after behavior testing was completed, mice were decapitated and 
their brains collected. Brains were then preserved and frozen at -80 degrees Celsius. Once all of 
the surgeries and behavior testing was completed, brain samples were collected from the frozen 
mouse brains. The targeted region for each injection was located and a sample was collected 
using a 0.5mm micro-puncher while the brain was mounted on a cryostat. Tissues were pooled 
based on location and type of injection (Jarid1c-siRNA/control-siRNA). Two tubes for each 
group were used and samples were taken from each side of the brain. Samples were placed in the 
two tubes randomly to avoid any laterality effect.  
 After all samples were collected, RNA was extracted using an RNAeasy kit (Qiagen, 
Valencia, CA). RNA samples were then sent to the Computational Genomics Core at Tufts 
University Center for Neuroscience Research to be analyzed for gene knockdown success. The 
genome-wide expression profile was determined using the GeneChip Mouse Gene 1.0 ST Array 
(Affymetrix, Santa Clara, CA). To ensure accurate measurement of gene expression, 27 probes 
were used to represent all 28,853 genes.  
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Results 
Brain injection with Jarid1c-siRNA results in knockdown of Jarid1c gene 
expression 
 
 To test the success of Jarid1c knockdown in the targeted areas, expression was quantified 
using the RT-PCR method. Samples from each brain region were analyzed on a real time PCR 
machine (ABI, Foster City, CA) and it was found that Jarid1c-siRNA treated samples showed a 
25% reduction of Jarid1c activity relative to control samples. This analysis confirms successful 
siRNA treatment.  
 
Object recognition was affected by Jarid1c knockdown in the hippocampus 
 
 In the object recognition test, mice with Jarid1c knockdown in the hippocampus spent 
less time with the novel object than the control mice (p=.014). This shows a significant memory 
deficit connected with a decrease in Jarid1c activity in the hippocampus (Figure 6).  
 In the prefrontal cortex and amygdala there was no significant difference in object 
recognition between those mice that received Jarid1c-siRNA or control-siRNA  
 
 
Figure 6: Jarid1c knockdown in the hippocampus 
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Anxiety was affected by Jarid1c knockdown in the prefrontal cortex 
 
 Anxiety was monitored for each mouse using the open field test. It was found that those 
mice with Jarid1c knockdown in the prefrontal cortex were significantly more anxious than the 
controls (p=.013). This test suggests that the Jarid1c gene in the prefrontal cortex has a relation 
to anxiety (Figure 7).  
 Knockdown of Jarid1c in the hippocampus and amygdala did not show any significant 
differences in anxiety levels between the knockdown mice and the controls  
 
 
Figure 7: Jarid1c knockdown in the prefrontal cortex 
 
Activity was not affected by Jarid1c knockdown 
 
 Activity was monitored for all of the mice tested in this study. It was found that when 
comparing the mice that received Jarid1c-siRNA with the mice that received the control- siRNA 
there was no significant difference in activity levels for any brain region (Figures 6 and 7). 
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Discussion 
 
 Using stereotaxic procedure to knock down Jarid1c activity in three different brain 
regions of the mouse yielded exciting results that significantly influence the study of X-linked 
mental retardation. Behaviors were observed in the Jarid1c knockdown mice that are indicative 
of similar behaviors seen in human XLMR patients. This makes the Jarid1c knockdown mouse 
an excellent model for XLMR studies.  
 Performing Jarid1c siRNA induced knockdown in the hippocampus showed a significant 
decrease in memory capability in the mice, as shown by the object recognition test. Jarid1c-
siRNA mice took significantly longer to spend 30 seconds with the novel object than the control-
siRNA mice. This shows a decreased ability to recognize the familiar object. Decreased 
cognition and memory disabilities are common symptoms of XLMR. The data strongly suggests 
that Jarid1c could have a role in causing these symptoms in humans.  
 siRNA knockdown of Jarid1c activity in the prefrontal cortex also led to behaviors 
similar to those seen in XLMR patients. The prefrontal cortex has been known to play important 
roles in social behavior in humans. Therefore, it was exciting to see that Jarid1c knockdown in 
the prefrontal cortex induced increased anxiety as shown in the open field test. Heightened 
anxiety levels are very prevalent in XLMR cases, especially autism. This mouse model shows a 
link between the role of Jarid1c in the prefrontal cortex and the common symptom of high 
anxiety levels in XLMR in humans.  
 No changes in activity were noticed between control and Jarid1c-siRNA treated mice. 
This is important because it supports the results of the anxiety test. If the activity levels were 
significantly different between the groups it could call into question results related to anxiety 
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levels. If activity levels had been affected, increased movement throughout the field in the open 
field test might have been due to hyperactivity and not lowered anxiety levels.   
 Using real-time PCR to determine the actual knockdown success is important for 
verifying results. If the knockdown was shown to be unsuccessful, then the behavior results 
could have been due to a lesion effect during stereotaxic injection, and not the siRNA. However, 
given the success of the knockdown (25%) the behavior results can be attributed to the success of 
the Jarid1c knockdown. It is important to note that while 25% may not seem like a significant 
knockdown, given the behavior results attributed to this knockdown it shows the importance of 
Jarid1c activity. 
 In addition to the hippocampus and the prefrontal cortex, the amygdala was also injected. 
However, there were no significant behavior results from this region. Possible reasons could be 
that Jarid1c does not play as important of a role in this region. On the other hand, it could have 
been due to location and complications with the stereotaxic procedure. The amygdala is 
extremely ventral in the brain, and because of this the injection needle must go through a lot of 
brain matter to reach the target area. Given the distance the needle must travel there is a higher 
likelihood that all mice, Jarid1c-siRNA and control-siRNA, could be affected by the procedure 
to the degree that any differences in behavior due to Jarid1c knockdown would be undetectable.  
 The results of this experiment provide a strong argument for the involvement of Jarid1c 
in XLMR, particularly in the brain regions of the hippocampus and prefrontal cortex. Further 
studies should pursue the pathway involving Jarid1c and investigate the genes that are down-
regulated by it. Looking further into the pathway will help to pinpoint the actual cause of these 
behaviors. Further research should investigate whether it is the specific knockdown of Jarid1c 
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that is causing behavior changes, or if the knockdown of Jarid1c causes an inactivity of another 
part of the pathway which in turn causes these behavior changes.  
 Additional future research should investigate the long term behavior changes caused by 
silencing Jarid1c in the brain. If Jarid1c is silenced permanently using a lentivirus approach, 
resulting long term behavior changes could be monitored. Without this investigation it will 
remain unknown whether behavioral changes might worsen with time, or whether a 
compensation mechanism will develop, allowing conditions to improve. In addition, the 
knockdown effect on different ages of mice should be investigated.  
 This study helped support the hypothesis that Jarid1c mutations have a causal effect on 
XLMR. It was found in particular that knockdown of Jarid1c in the hippocampus and prefrontal 
cortex caused reduced feature recognition and increased anxiety, respectively. Microarray 
analysis indicated that knockdown was 25% successful relative to the non-targeting control-
siRNA and that expression of Jarid1c was not affected in nearby striatal regions. Lastly, it was 
found that expression of Jarid1d, a close homologue of Jarid1c, was not affected by the 
knockdown procedure, which argues against an off-target effect.  
 It is hoped that these results and future experiments involving Jarid1c’s involvement in 
XLMR will help to find the cause of these associated symptoms. Given these results and the 
results of future suggested studies, a cure for XLMR diseases will be attainable.  
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Appendix A: Stereotaxic injection procedure 
 
1. Autoclave surgery tools: scalpel blade holder, forceps, staple administrator, staples, and 
cotton swabs. 
2. Day of surgery: set up heating pad on surgery table and place mice cage half on to begin 
acclimation.  
3. Wipe down all surgery areas with 70% ethanol. 
4. Turn on bead sterilizer. 
5. Lay down chux pads on the surgery area and preparation area. 
6. Place stereotaxic instrument on chux pad on surgery table and wipe down with 70% 
ethanol.  
7. Set up preparation area with a gram scale, the induction chamber, nose cone, cotton 
swabs and disinfecting solutions (surgical scrub, 70% ethanol, and surgical paste).  
8. Lay out a drape next to the surgical instrument using sterile techniques. Open the surgical 
pack and dump the instruments into the sterile field. Also dump sterile cotton swabs, and 
a 10 blade onto the drape. Finally, lay a pack of sterile gloves next to the drape.  
9. Put on hair net, face mask and non-sterile gloves. 
10. Load a 1µL syringe with injectable (Jarid1c-siRNA or control siRNA) after wiping down 
with 70% ethanol and then sterilizing it via the bead sterilizer. Then load into the 
stereotaxic instrument. 
11. Once the mice have been in the room for at least 10 minutes to acclimate, remove first 
mouse, place in induction chamber and turn on isoflourine delivering at 4% for about 2-4 
minutes or until the animal’s respiratory rate has slowed significantly. Make sure oxygen 
is set at around 1 and exhaust is set a little above 1.  
12. When the mouse’s breathing rate has decreased a significant amount, turn on the 
isoflourine to the nose cone on the preparation table, reducing the flow to 2-2.5% and 
turn off the flow to the induction chamber. Move mouse from induction chamber to nose 
cone immediately after. 
13. Perform a toe press to make sure the mouse is fully under.  
14. Weigh the animal and record weight once you get no response from the toe press test. 
Once weight is gathered immediately place back on nose cone.  
15. Begin pulling hair from top of the head until it is clear from ear to ear and from the eye 
line to the base of the skull.  
16. Begin scrubbing. Start with the surgical scrub, then 70% ethanol applied with the cotton 
swabs and repeat 3 times. End with the surgical paste. Begin scrubbing at the center of 
the hairless area moving outward in a circular motion.  
17. When scrubbing is complete, turn on isoflourine into the nose cone on the stereotaxic 
instrument. Turn off flow to nose cone in preparation area. 
18. Move mouse to surgical instrument. Make sure nose is in cone and set incisors into hole 
on bar below nose cone to assist with stability.  
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19. Move the two ear bars so they are snug against the side of the mouse head to ensure 
stability and keep the head parallel to the table. Bars should be placed right at the ears 
and secured tightly while making sure that the pressure is light but secure. Test stability 
by pressing the top of the head with a sterile cotton swab.  
20. Take off non-sterile gloves and put on sterile gloves using the proper sterile technique.  
21. Give around 0.02CC of bupivicaine, a local anesthetic, subcutaneously at the incision 
site. 
22. Make a 3-4cm midline incision on the top of the scalp.  
23. Expose the skull and scrap skull lightly with scalpel. Then, wipe with a sterile cotton 
swab.  
24. Locate the bregma and move the syringe so that it is just touching the bregma. Zero the x, 
y and z coordinates of the injection machine.  
25. Move the syringe to the coordinates for the targeted injection site:  
a. Hippocampus - Lateral +2/-2 mm, Posterior -2.0 mm, and Ventral -1.6 mm 
b. Prefrontal Cortex – Lateral +1.6/-1.6 mm, Anterior 2.8 mm, and Ventral   -1.3 
mm  
c. Amygdala – Lateral +2.6/-2.6 mm, Posterior -1.5 mm, and Ventral -5.7 mm  
26. Note where the syringe is placed and move it up out of the way. At the spot where the 
syringe will enter drill a hole using a dental drill. While drilling double check placement 
by moving the syringe down. 
27. Once through the skull, slowly move the syringe down to the ventral coordinate and 
begin injection. 
28. Injection will last for 5 minutes. Once complete leave in place for an additional 2-5 
minutes.  
29. After the wait period, slowing remove needle and replace syringe with same injectable 
before moving to the other side.  
30. Re-zero the coordinates at the bregma and move to the opposite side of the skull 
maintaining the same anterior/posterior and ventral coordinates.  
31. Drill at the spot of injection and slowly insert needle.  
32. Inject at the same 5 minute pace, and wait the 2-5 minutes before removing.  
33. Once needle is fully removed, turn off isoflourine and oxygen and get out 2 clamps and 
clamp applicator.  
34. Using tweezers at the base of the incision to hold incision together, place 2 clamps on 
incision to keep it closed and allow it to heal. If incision doesn’t look fully closed, a small 
amount of tissue glue can be applied.  
35. Record time that mouse was taken off of gas.  
36. Give appropriate amount of Ketoprofen. Ketoprofen is to be given at a dose of 10mg/kg 
once diluted appropriately (see directions on Ketoprofen bottle). Give subcutaneously 
and record dose on surgery card. 
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37. Place mouse in a prepared, clean, recovery cage with a few food pellets on the ground 
and water available. Make sure recovery cage is placed half on a heating pad. 
38. Watch the mouse during recovery and record any unusual behavior as well as time of full 
alertness. Record on surgery card the time when the mouse is viewed as BAR. Mouse 
should not take longer than one hour to be fully recovered.  
 
**If any problems arise during surgery or mouse does not fully recover within one hour, 
immediately call the PI or the DTRR veterinarian on duty** 
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Appendix B: Surgery details 
 
Mouse ID Date of Surgery Injection site siRNA Injection 
550 627 2/18/2009 Prefrontal Cortex Control 
562 887 2/18/2009 Prefrontal Cortex Jarid1c 
567 840 2/18/2009 Medial Amygdala Jarid1c 
581 085 2/18/2009 Medial Amygdala Control 
032 343 2/25/2009 Dorsal Hippocampus Control 
588 000 2/25/2009 Dorsal Hippocampus Jarid1c 
540 054 3/4/2009 Dorsal Hippocampus Control 
542 886 3/4/2009 Prefrontal Cortex Jarid1c 
571 088 3/4/2009 Prefrontal Cortex Control 
582 837 3/4/2009 Dorsal Hippocampus Jarid1c 
563 803 3/18/2009 Dorsal Hippocampus Jarid1c 
575 554 3/18/2009 Medial Amygdala Control 
581 094 3/18/2009 Dorsal Hippocampus Control 
581 328 3/18/2009 Medial Amygdala Jarid1c 
539 860 3/21/2009 Medial Amygdala Jarid1c 
552 828 3/21/2009 Medial Amygdala Control 
558 619 3/21/2009 Prefrontal Cortex Jarid1c 
577 564 3/21/2009 Prefrontal Cortex Control 
023 829 3/25/2009 Dorsal Hippocampus Control 
536 612 3/25/2009 Medial Amygdala Jarid1c 
544 295 3/25/2009 Medial Amygdala Control 
574 574 3/25/2009 Dorsal Hippocampus Jarid1c 
019 607 4/1/2009 Dorsal Hippocampus Jarid1c 
543 058 4/1/2009 Dorsal Hippocampus Jarid1c 
836 060 4/1/2009 Prefrontal Cortex Jarid1c 
No ID 4/1/2009 Prefrontal Cortex Jarid1c 
 
